MX367271B - Uso de moduladores de microarn. - Google Patents

Uso de moduladores de microarn.

Info

Publication number
MX367271B
MX367271B MX2017000916A MX2017000916A MX367271B MX 367271 B MX367271 B MX 367271B MX 2017000916 A MX2017000916 A MX 2017000916A MX 2017000916 A MX2017000916 A MX 2017000916A MX 367271 B MX367271 B MX 367271B
Authority
MX
Mexico
Prior art keywords
methods
skin
treating skin
active agents
screening
Prior art date
Application number
MX2017000916A
Other languages
English (en)
Inventor
W Lyga John
Santhanam Uma
Raaj Khusial Permanan
Original Assignee
Avon Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Prod Inc filed Critical Avon Prod Inc
Publication of MX367271B publication Critical patent/MX367271B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a métodos para prevenir, mejorar o reducir los signos dermatológicos del envejecimiento, que emplean agentes activos que suprimen o disminuyen la expresión de microARN en el fibroblasto dérmico, lo que da como resultado un incremento en la producción de colágeno, elastina y/o fibrilina en la piel. También se proveen métodos para detectar la actividad contra microARN específicos y métodos para utilizar agentes activos identificados mediante el protocolo de prueba en el tratamiento de la piel.
MX2017000916A 2010-12-28 2011-11-21 Uso de moduladores de microarn. MX367271B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/979,695 US8455518B2 (en) 2010-12-28 2010-12-28 Method of treating skin with microRNA modulators
PCT/US2011/061656 WO2012091824A1 (en) 2010-12-28 2011-11-21 METHOD OF TREATING SKIN WITH microRNA MODULATORS

Publications (1)

Publication Number Publication Date
MX367271B true MX367271B (es) 2019-08-12

Family

ID=46317882

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000916A MX367271B (es) 2010-12-28 2011-11-21 Uso de moduladores de microarn.
MX2013006059A MX345299B (es) 2010-12-28 2011-11-21 Uso de moduladores de microarn.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013006059A MX345299B (es) 2010-12-28 2011-11-21 Uso de moduladores de microarn.

Country Status (12)

Country Link
US (2) US8455518B2 (es)
EP (2) EP2987534B1 (es)
JP (1) JP5918783B2 (es)
CN (2) CN103249409B (es)
AR (1) AR084598A1 (es)
BR (1) BR112013014597B1 (es)
CA (2) CA2817395C (es)
HU (1) HUE068372T2 (es)
MX (2) MX367271B (es)
PL (2) PL2658537T3 (es)
TW (1) TWI605833B (es)
WO (1) WO2012091824A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588593B1 (en) 2010-06-30 2017-08-23 Avon Products, Inc. Compositions and methods for stimulating magp-1 to improve the appearance of skin
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
JP6120398B2 (ja) * 2012-11-02 2017-04-26 国立大学法人三重大学 水溶性フィブリリン組成物による弾性線維増強法
WO2014092686A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Stephanotis jasminoides extracts and methods of use
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
TW201422246A (zh) 2012-12-11 2014-06-16 Avon Prod Inc 藉由調節ｗｉｐｉ－１改善皮膚老化外觀之方法
US9186316B2 (en) 2012-12-11 2015-11-17 Avon Products, Inc. Stephanotis jasminoides extracts and methods of use
US9445981B2 (en) * 2012-12-20 2016-09-20 Avon Products, Inc PLOD-2 stimulators and their use in the treatment of skin
CN110205366B (zh) * 2018-02-28 2022-06-21 伽蓝（集团）股份有限公司 一种皮肤内源性老化靶标的筛选方法及改善皮肤内源性老化的活性物及其筛选方法
CN111041082B (zh) * 2018-10-11 2023-11-07 伽蓝（集团）股份有限公司 一种以皮肤光老化靶标筛选改善皮肤光老化的活性物的方法及改善皮肤光老化的活性物
CN111249466B (zh) * 2020-03-14 2022-04-15 浙江大学医学院附属第一医院 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918023D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
EP2447370B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
WO2006133588A1 (en) * 2005-06-13 2006-12-21 Oncalis Ag ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
JP5192380B2 (ja) * 2005-09-08 2013-05-08 株式會社アモーレパシフィック 皮膚老化防止用皮膚外用剤組成物
EP2182969B1 (en) 2007-07-31 2016-11-16 The Board of Regents of The University of Texas System A micro-rna family that modulates fibrosis and uses thereof
EP2187896B1 (en) * 2007-07-31 2016-01-13 The Board of Regents of The University of Texas System Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
EP2588593B1 (en) * 2010-06-30 2017-08-23 Avon Products, Inc. Compositions and methods for stimulating magp-1 to improve the appearance of skin
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
CN103561718B (zh) * 2010-12-30 2020-06-16 雅芳产品公司 皮肤中动力蛋白的调节

Also Published As

Publication number Publication date
US8455518B2 (en) 2013-06-04
CA2817395A1 (en) 2012-07-05
WO2012091824A1 (en) 2012-07-05
EP2658537A4 (en) 2014-06-25
CA3010395C (en) 2020-12-15
EP2987534A1 (en) 2016-02-24
CN103249409A (zh) 2013-08-14
EP2987534B1 (en) 2024-07-10
BR112013014597A2 (pt) 2016-09-20
HK1206591A1 (en) 2016-01-15
HUE068372T2 (hu) 2024-12-28
HK1187251A1 (zh) 2014-04-04
CA2817395C (en) 2019-03-05
MX2013006059A (es) 2013-07-03
PL2658537T3 (pl) 2015-08-31
CA3010395A1 (en) 2012-07-05
TW201231078A (en) 2012-08-01
US20130253053A1 (en) 2013-09-26
CN103249409B (zh) 2016-07-06
BR112013014597B1 (pt) 2020-06-30
CN104622704B (zh) 2017-12-22
EP2658537A1 (en) 2013-11-06
CN104622704A (zh) 2015-05-20
EP2658537B1 (en) 2015-04-29
TWI605833B (zh) 2017-11-21
US8865740B2 (en) 2014-10-21
US20120165373A1 (en) 2012-06-28
AR084598A1 (es) 2013-05-29
MX345299B (es) 2017-01-24
JP5918783B2 (ja) 2016-05-18
JP2014509307A (ja) 2014-04-17
PL2987534T3 (pl) 2024-11-12

Similar Documents

Publication Publication Date Title
MX367271B (es) Uso de moduladores de microarn.
WO2012110996A3 (en) A method and apparatus for cosmetic skin treatment
MX352165B (es) Compuestos con actividad anti-envejecimiento.
IN2015DN02938A (es)
SG10201914117QA (en) Treatment Of Myelosuppression
PH12013501524A1 (en) Topical minocycline compositions and methods of using the same
GB2481760B (en) Devices for dermatological treatment
WO2011130389A3 (en) System and method for microablation of tissue
MX354734B (es) Modulación de dineína en la piel.
WO2013028262A3 (en) Systems and methods for stimulating cellular function in tissue
MX2012002987A (es) Composicion cosmetica.
WO2011069010A3 (en) Amantadine compositions and methods of use
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
EP2537513A3 (en) Use of anogeissus extract for fibrillin production in skin
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
HK1207308A1 (en) Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
WO2015081306A3 (en) Peptide tyrosinase activators
GB201202561D0 (en) Treatment of skin disorders
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
HK1209038A1 (en) Small molecules that promote skin regeneration
WO2012024403A3 (en) Methods of treating cellulite
WO2013091894A3 (en) Topical compositions
IN2012DN00546A (es)